Janssen Biologics B.V., of Leiden, the Netherlands, part of Johnson & Johnson, withdrew its application seeking a change to the marketing authorization for Simponi (golimumab) to add a new pharmaceutical form of intravenous (I.V.) administration for the treatment of adults with moderately to severely active rheumatoid arthritis.